QTQixing Tan

Qixing Tan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qixing Tan has a total of 26 co-authors. Here are the top co-authors by number of shared publications:

  • Zhen Huang

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

    4 shared publications
  • Bin Lian

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

    3 shared publications
  • Fa-You Lv

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

    3 shared publications
  • Binjie Chen

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China

    2 shared publications
  • Chang-Yuan Wei

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China

    2 shared publications
  • Jian Liao

    Department of Breast Surgery, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China

    2 shared publications

Latest Publications

  • Open Access

    CPT1A exacerbates trastuzumab-induced cardiotoxicity via promotion of mitochondrial dysfunction

    by Yukun Liu, Binjie Chen, Hanqing Li, Wenhai Zhang, Bin Lian, Zhen Huang, Qinghong Qin, Qixing Tan, Chang-Yuan Wei


  • Open Access

    Gut microbiota and glycochenodeoxycholic role in liver metastasis of breast cancer

    by Liping Yan, Qixing Tan, Jia Zhu, Yongfei He, Peng Tao, Jianxin He


  • Open Access

    Survival prognosis evaluation in advanced breast cancer patients: a study on the application of the advanced lung cancer inflammation index

    by Chunfeng Liang, Chunyan Yang, Qiujiao Yang, Yuchen Tang, Wenhai Zhang, Qixing Tan, Qinghong Qin

    Background: Inflammation and nutritional status play critical roles in tumor initiation and progression. Advanced Lung Cancer Inflammation Index (ALI) has gained widespread attention as a novel biomarker for cancer prognosis evaluation.Methods: This retrospective study analyzed 163 advanced breast cancer patients with distant metastasis (Guangxi Medical University Cancer Hospital, 2016-2023). Patients were stratified into high-ALI (n=64) and low-ALI (n=99) groups via K-means clustering. Kaplan-Meier survival curves with log-rank testing were used to assess survival differences, while Cox proportional hazards models were employed to evaluate the independent prognostic value of ALI. The predictive performance of ALI was assessed using time-dependent ROC curves.Results: High ALI correlated with superior overall survival (log-rank p=0.0024) [HR=2.493 (95%CI 1.350-4.606) p = 0.004]. Multivariate analysis confirmed ALI as an independent prognostic factor (HR=0.39, 95% CI 0.16-0.95, p=0.037). ALI demonstrated stable predictive accuracy with 3-year AUC=0.645 and 5-year AUC=0.650 (C-index=0.65). Subgroup analyses confirmed prognostic consistency across clinical characteristics (p-interaction>0.05).Conclusion: ALI is an independent prognostic factor for advanced breast cancer patients with good predictive ability. It provides an important supplementary prognostic marker for clinical practice and can help optimize personalized treatment strategies.


  • Open Access

    Locoregional recurrence and survival of breast−conserving surgery compared to mastectomy following neoadjuvant chemotherapy in operable breast cancer

    by Fa-You Lv, Zongming Mo, Binjie Chen, Zhen Huang, Qinguo Mo, Qixing Tan

    Background: The risk of locoregional recurrence (LRR) and the long-term prognosis of breast-conserving surgery (BCS) after neoadjuvant chemotherapy (NAC) are still controversial. This study aimed to evaluate oncological outcomes for patients undergoing BCS after NAC and determine LRR and survival predictors.Methods: This study was a retrospective cohort study of patients with locally advanced breast cancer (LABC) who received NAC and underwent BCS or mastectomy from June 2011 to November 2020. LRR, disease-free survival (DFS), and overall survival (OS) were compared in patients undergoing BCS or mastectomy. Univariate and multivariate analyses were performed to determine LRR, DFS, and OS predictors.Results: A total of 585 patients were included, of whom 106 (18.1%) underwent BCS and 479 (81.9%) underwent a mastectomy. The LRR rate was 11.3% in the BCS group and 16.3% in the mastectomy group, revealing no significant difference(p = 0.200). In patients who underwent BCS, clinical lymph node status, histological grade and pathological complete response (pCR) were independent factors to predict LRR. There was no significant difference in DFS and OS between the BCS and the mastectomy groups. Multivariable analysis showed that lymph node status, histological grade, molecular subtypes, pCR and Miller&Payne (M&P) classification were independent predictors of DFS. Lymph node status, molecular subtypes and pCR were independent predictors of OS. BCS or mastectomy was not an independent predictor of DFS or OS.Conclusion: Compared with mastectomy, BCS after NAC may not increase the risk of local recurrence or mortality, BCS can be performed in selected patients with small tumor size and good response to NAC.


  • Open Access

    IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis

    by Jian Liao, Qing-Hong Qin, Fa-You Lv, Zhen Huang, Bin Lian, Chang-Yuan Wei, Qin-Guo Mo, Qi-Xing Tan

    IKKα has been shown to be responsible of multiple pro-tumorigenic functions and therapy resistance independent of canonical NF-κB, but its role in acquired chemotherapy resistance in breast cancer remains unclarified. In this study, we obtained pre-treatment biopsy and post-treatment mastectomy specimens from a retrospective cohort of triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy(NAC) (n = 43). Immunohistochemical methods were used to detect the expression of IKKα before and after NAC, and the relationship between IKKα and the pathologic response to NAC was examined. In addition, we developed a new ADR-resistant MDA-MB-231 cell line(MDA-MB-231/ADR) and analyzed these cells for changes in IKKα expression, the role and mechanisms of the increased IKKα in promoting drug resistance were determined in vitro and in vivo. We demonstrated that the expression of IKKα in residual TNBC tissues after chemotherapy was significantly higher than that before chemotherapy, and was positively correlated with lower pathological reaction. IKKα expression was significantly higher in ADR-resistant TNBC cells than in ADR-sensitive cells, IKKα knockdown results in apoptotic cell death of chemoresistant cells upon drug treatment. Moreover, IKKα knockdown promotes chemotherapeutic drug-induced tumor cell death in an transplanted tumor mouse model. Functionally, we demonstrated that IKKα knockdown significantly upregulated the expression of cleaved caspase 3 and Bax and inhibited the expression of Bcl-2 upon ADR treatment. Our findings highlighted that IKKα exerts an important and previously unknown role in promoting chemoresistance in TNBC, combining IKKα inhibition with chemotherapy may be an effective strategy to improve treatment outcome in chemoresistant TNBC patients.


  • Open Access

    IKKα inhibition re-sensitizes acquired adriamycin-resistant triple negative breast cancer cells to chemotherapy-induced apoptosis

    by Jian Liao, Qing-Hong Qin, Fa-You Lv, Zhen Huang, Bin Lian, Chang-Yuan Wei, Qin-Guo Mo, Qi-Xing Tan

    IKKα has been shown to be responsible of multiple pro-tumorigenic functions and therapy resistance independent of canonical NF-κB, but its role in acquired chemotherapy resistance in breast cancer remains unclarified. In this study, we obtained pre-treatment biopsy and post-treatment mastectomy specimens from aretrospective cohort of triple-negative breast cancer (TNBC) patients treated with neoadjuvant chemotherapy(NAC) (n = 43). Immunohistochemical methods were used to detect the expression of IKKα before and after NAC, and the relationship between IKKα and the pathologic response to NAC was examined. In addition, we developed a new ADR-resistant MDA-MB-231 cell line(MDA-MB-231/ADR) and analyzed these cells for changes in IKKα expression, the role and mechanisms of the increased IKKα in promoting drug resistance were determined in vitro and in vivo. We demonstrated that the expression of IKKα in residual TNBC tissues after chemotherapy was significantly higher than that before chemotherapy, and was positively correlated with lower pathological reaction. IKKα expression was significantly higher in ADR-resistant TNBC cells than in ADR-sensitive cells, IKKα knockdown results in apoptotic cell death of chemoresistant cells upon drug treatment. Moreover, IKKα knockdown promotes chemotherapeutic drug-induced tumor cell death in an transplanted tumor mouse model. Functionally, we demonstrated that IKKα knockdown significantly upregulated the expression of cleaved caspase 3 and Bax and inhibited the expression of Bcl-2 upon ADR treatment. Our findings highlighted that IKKα exerts an important and previously unknown role in promoting chemoresistance in TNBC, combining IKKα inhibition with chemotherapy may be an effective strategy to improve treatment outcome in chemoresistant TNBC patients.